TY - JOUR T1 - Implementation of a multi-modal training program for the management of comorbid mental disorders in drug and alcohol settings: Pathways to Comorbidity Care (PCC) JF - medRxiv DO - 10.1101/2021.03.18.21253927 SP - 2021.03.18.21253927 AU - Eva Louie AU - Kirsten C. Morley AU - Vicki Giannopoulos AU - Gabriela Uribe AU - Katie Wood AU - Christina Marel AU - Katherine L Mills AU - Maree Teesson AU - Michael Edwards AU - Steven Childs AU - David Rogers AU - Adrian Dunlop AU - Andrew Baillie AU - Paul S. Haber Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253927.abstract N2 - Background Clinical guidelines recommend evidence-based treatments for comorbid mental and substance use disorders but these are not reliably translated into practice. We aimed to evaluate the impact of the Pathways to Comorbidity Care (PCC) training program for alcohol and other drug (AOD) clinicians to improve the management of comorbidity and to identify barriers and facilitators of implementation according to the Consolidated Framework for Implementation Research (CFIR).Methods A controlled before-and-after study using PCC training was conducted across 6 matched sites in Australia including 35 clinicians. Controls received standard workplace training. PCC training included seminar presentations, workshops conducted by local ‘clinical champions’, individual clinical supervision, and access to an online information portal. A mixed methods approach examined i) identification (screening, assessment) and treatment (treatment, referral) of comorbidity in practice (N = 10 clinical files per clinician), ii) self-efficacy, knowledge and attitudes of clinicians, iii) barriers and facilitators of implementation.Results Significant improvements were observed in the PCC group but not the control sites with regards to the rate of clinical files showing identification of comorbidity (+50% v −12% change from baseline respectively; X2 (1, N = 340) = 35.29, p = .01) with only a trend for improvements in the rate of files demonstrating treatment of comorbidity (X2 (1, N = 340) = 10.45, p = .06). There were significant improvements in the PCC relative to the control group for clinician self-efficacy (F (1,33) = 6.40, p = .02) and knowledge and attitudes of comorbidity monitoring (F (1,33) = 8.745, p = .01). Barriers included inner setting (e.g. allocated time for learning) and characteristics of individuals (e.g. resistance). Facilitators included intervention characteristics (e.g. credible sources), inner setting (e.g. leadership) and outer setting domains (e.g. patient needs). Clinical champions were identified as an important component of the implementation process.Conclusions The PCC training package effectively improved identification of comorbidity, self-efficacy and attitudes towards screening and monitoring of comorbidity. Specific barriers included provision of allocated time for learning. Specific facilitators included provision of a credible clinical supervisor, strong leadership engagement and an active clinical champion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a Translational Research grant from the New South Wales Health (PH, KM, AB), a Translational Research Fellowship (KM), a Research Training Program (EL) and MRFF/NHMRC Practitioner Research Fellowship (PH). The authors wish to thank our clinical colleagues who assisted with recruitment at the participating centres. The Comorbidity Guidelines was funded by the Australian Government Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Human Ethics Review Committees of the Sydney Local Health District, South Western Sydney Local Health District, Central Coast Local Health District, Hunter New England Research Ethics and Governance Office which covered two participating services, and Mid North Coast Local Health District (X16-0440 & HREC/16/RPAH/624)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request ER -